Stifel lowered the firm’s price target on Sage Therapeutics to $20 from $26 and keeps a Hold rating on the shares following the Q1 report. The firm thinks Sage is in the process of validating postpartum depression as a real market opportunity. However, the analyst still finds it hard to have conviction in Huntington’s disease and Alzheimer’s disease, and also views the SAGE-324 ET program as “high risk.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
- Sage Therapeutics price target lowered to $19 from $34 at Scotiabank
- Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer
- H.C. Wainwright concerned over Sage’s next readouts after SAGE-718 miss
